Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02767089 · ClinicalTrials.gov registry record · Phase 1
The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers
A Phase 1 study of Healthy Adults, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 1
- Study location
NCT02767089 is a Phase 1 study of Healthy Adults that has completed, run by Pfizer. The registered enrollment target is 37 participants, below the 85-participant average among 33 other Healthy Adults trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02767089, a Phase 1 study of Healthy Adults, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to further access the utility of biochemical and clinical biomarkers for glucocorticoid-mediated anti-inflammatory effects and safety endpoints against which dissociated agonists of the glucocorticoid receptor (DAGR) will be evaluated in adult healthy volunteers.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Prednisone
Study Locations (1)
Michigan
- Jasper Clinic, Inc. - Kalamazoo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2005-10 |
| Est. Completion | 2006-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02767089
The ClinicalTrials.gov registry entry for NCT02767089 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 85-participant average among 33 other Healthy Adults trials with a reported enrollment target (56% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Adults appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02767089 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT02767089 about?
NCT02767089 is a clinical study titled "The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers". The purpose of this study is to further access the utility of biochemical and clinical biomarkers for glucocorticoid-mediated anti-inflammatory effects and safety endpoints against which dissociated agonists of the glucocorticoid receptor (DAGR) will be evaluated in adult healthy volunteers.
What is the current status of trial NCT02767089?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2005-10. Estimated completion is 2006-03.
What conditions does trial NCT02767089 study?
This clinical trial studies the following conditions: Healthy Adults.
What interventions are being tested in trial NCT02767089?
The interventions under investigation include: Placebo (DRUG), Prednisone (DRUG).
Who is sponsoring clinical trial NCT02767089?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02767089 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Adults
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of EDG-15400 in Healthy Adults
RECRUITING · Phase 1
-
A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060
RECRUITING · Phase 1
-
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults
RECRUITING · Phase 1
-
Safety and Efficacy of Injectable Klotho Plasmid Gene Therapy in Humans
RECRUITING · Phase 1
-
Tracing the Metabolic Flux of Orally Administered NAD+ Precursors
RECRUITING · Phase 1
-
A Study to Determine the Effect of KP-001 on Metformin and Midazolam Pharmacokinetics and the Effect of Clarithromycin on KP-001 Pharmacokinetics in Healthy Adult Participants
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.